academic journalism

Suppression of Myocardial Injury Markers following Percutaneous Coronary Interventions by Pre-treatment with Carvedilol


avatar Abdolrasoul Moloudi 1 , * , avatar Feridoun Sabzi 1 , avatar Shirin Rashidi 1

1 Emam Ali Cardiovascular Center, Kermanshah University of Medical Sciences, Kermanshah, Iran

How to Cite: Moloudi A, Sabzi F , Rashidi S . Suppression of Myocardial Injury Markers following Percutaneous Coronary Interventions by Pre-treatment with Carvedilol. Int Cardio Res J. 2017;6(3):e12805.


International Cardiovascular Research Journal: 6 (3); e12805
Published Online: September 30, 2012
Article Type: Research Article
Received: May 16, 2017
Accepted: July 09, 2012


Background: Retrospective studies and clinical trials have indicated that β-receptor blockers have an influential role in improving survival and reducing risk of recurrent infarction in patients with myocardial infarction. However, there is still controversy regarding the effects of β-receptor blockers on the markers of myocardial infarction following percutaneous coronary interventions (PCI).
Objective: The aim of this study was to evaluate the pre-treatment effect of Carvedilol on markers of myocardial injury in patients undergoing elective PCI.
Method and Materials: In this clinical trial patients undergoing elective PCI were categorized randomly in the Carvedilol group including 100 patients who received two doses of 12.5 mg, 6 and 12 hours prior to PCI, and the control group (105 patients). Blood samples were obtained to analyse cardiac biomarker, 12 and 24 hours after PCI.
Results: The clinical features were not significantly different between the two groups. A increase in the level of Troponin I was observed in the control group 24 hours following PCI (P=0.042), whereas this rise in troponin I was slight and insignificant in the Carvedilol group (P>0.05). some difference was observed between the two groups in regard to the level of CPK-MB after PCI (P=0.041).
Conclusion: The findings of our study indicate that pre-treatment with Carvedilol confers cardio-protection by limiting the rise of markers of myocardial injury following PCI.


The full text is available in PDF.


  • 1.

    The references are available in PDF.

© 2017, Shiraz University of Medical Sciences.